Skip to main content
S 4397 116th Congress Senate Health Congressional oversight Health care coverage and access Health personnel Health promotion and preventive care Health technology, devices, supplies Medicaid Medical research Minority health Prescription drugs Research administration and funding Sex and reproductive health Women's health

Uterine Fibroid Research and Education Act of 2020

Introduced: August 3, 2020 See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Aug 3, 2020
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Aug 3, 2020
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Uterine Fibroid Research and Education Act of 2020

This bill directs specified components of the Department of Health and Human Services to take certain actions to address uterine fibroids (i.e., muscular tumors that grow in the wall of the uterus and may cause pain, heavy menstrual bleeding, and reproductive issues).

Specifically, the National Institutes of Health (NIH), working through the Office of Research on Women's Health, must undertake research activities on uterine fibroids. In carrying out this research, the office must coordinate with specified components of the NIH and other federal agencies.

In addition, the Centers for Medicare & Medicaid Services must (1) collect data from Medicaid and the Children's Health Insurance Program about treatment and services related to uterine fibroids, and (2) develop a report in coordination with federal partners on federal and state expenditures for these treatments and services.

Additionally, the Centers for Disease Control and Prevention (CDC), the Health Resources Service Administration (HRSA), and the Agency for Healthcare Research and Quality (AHRQ) must disseminate information about uterine fibroids, including the elevated risk for minority women and information regarding available treatments. Specifically, the CDC shall disseminate the information to the public, while HRSA and AHRQ shall disseminate it to health care providers.

What's happening now August 3, 2020

Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Related & companion bills 1
  • HR 6383 Identical bill Uterine Fibroid Research and Education Act of 2020
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 3
All 3 Democratic 3
D
Blumenthal, Richard
Connecticut · Sep 17, 2020
 D
Booker, Cory A.
New Jersey · Aug 3, 2020
 D
Van Hollen, Chris
Maryland · Aug 3, 2020
Cite this page click to expand
APA
U.S. Congress. (2026). S. 4397: Uterine Fibroid Research and Education Act of 2020. 116th Congress. Open America. https://openamerica.io/bill/116-S-4397/
MLA
"S. 4397: Uterine Fibroid Research and Education Act of 2020." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-S-4397/.
Bluebook (legal)
S. 4397, 116th Cong. (2026), https://openamerica.io/bill/116-S-4397/.
Markdown link
[S. 4397: Uterine Fibroid Research and Education Act of 2020](https://openamerica.io/bill/116-S-4397/)
Report a problem